QSRC & The University College London Hospitals NHS Foundation Trust have been shortlisted as finalist in the Public/Private Partnership of the Year category for the Health Investor Awards 2017.
In April 2016, NHS England (“NHSE”) awarded contracts for the provision of specialist Intracranial Stereotactic Radiosurgery (“SRS”) and Stereotactic Radiotherapy Services (“SRT”). The University College London Hospitals NHS Foundation Trust (“UCLH”) was successful in being awarded a seven year contract as the Supra Centre for the South of England serving a population of 31.3m. It is the only centre in England designated to receive referrals for all NHS commissioned indications whatever the age of the patient. This was announced publically on the 19th June by NHSE.
The Supra Centre is a partnership between UCLH and QSRC Ltd (“QSRC”). It derives a significant number of strengths from a) the well established integration between the diverse and many areas of expertise of UCLH, comprising some of the UK’s world-renowned medical research centres and hospitals b) the experience of Medical Equipment Solutions Ltd (“MESL”) in developing, financing and operating niche high capital value technology based healthcare solutions including other SRS facilities. For the paediatric service it also brings together the world leading expertise of Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”).
Located at the National Hospital for Neurology and Neurosurgery, Queens Square, London, the Gamma Knife Centre is at the core of the Supra Centre. Originally opened in 2013 it was built, developed, financed and is operated by QSRC Ltd with UCLH providing clinical and support services. The development was funded privately by a combination of equity and asset lease finance. For the new NHS contract UCLH is the lead contractor and QSRC is sub-contractor.
An innovative PPP model has been adopted. The new service requirements of NHSE are met in full with no investment of scarce public capital. The service is provided at fixed per patient tariff at significantly lower than 2015/16 per-patient prices with total risk transfer i.e. no patient volume guarantees and no regular payment as other forms of PPP.
Over the seven year contract period the centre is anticipated to offer treatment to more than 9000 NHS patients (some 20% of England patient volumes). The number of patients benefiting from SRS/SRT nationally is set to increase from just over 2,400 in 2014/15 to 6,200 patients a year by 2018/9, forming a concrete step towards the implementation of NHS England’s Cancer Strategy.